Objective
Epilepsy is the most common chronic neurological disorder, affecting ~50 million people. Major challenges in epilepsy include non-responsiveness to treatment and no effect on disease progression provided by anti-epileptic drugs. Over the past decade, particular attention has been paid to dysfunction of cerebral vasculature and inflammatory processes as important players in epileptogenic processes, with a specific emphasis on failure of the blood–brain barrier (BBB). The BBB is a complex cellular network forming a continuous cellular barrier separating the CNS from the bloodstream. A functional BBB is crucial in maintaining brain homeostasis and to prevent the entry of toxic compounds and immune cells into the CNS. During pathology, however, the permeability of the BBB may increase with the resulting entry into the CNS of blood-borne molecules and cells. Leakage of the BBB is one of the earliest characteristic pathophysiological disturbances following status epilepticus and may play an important role in the development of epilepsy. Consequently, drugs targeting BBB function may represent novel treatment strategies in epilepsy. The purinergic ATP-gated P2X7 receptor has gained much attention recently as novel target in the treatment of epilepsy. Expressed on all cell types in the CNS including endothelial cells, P2X7 has been associated with numerous damaging processes pertinent to epileptogenesis, such as inflammation and opening of the BBB. ATP and the P2X7 downstream target Interleukin-1β contribute to the disruption of the BBB and P2X7 antagonism protects against BBB disruption during intracerebral hemorrhage. To date, however, we do not know whether seizure-induced changes of the BBB are dependent on P2X7 signaling, and whether this process can be targeted. By using newly developed transgenic animal models, RNA sequencing and cutting edge imaging techniques we will determine how P2X7 impacts on BBB integrity during seizures and what genes are regulated by P2X7.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine neurology epilepsy
- engineering and technology electrical engineering, electronic engineering, information engineering information engineering telecommunications telecommunications networks mobile network
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pathology
- medical and health sciences basic medicine physiology homeostasis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
D02 YN77 DUBLIN 2
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.